Jane Street
PRLD icon

Jane Street’s Prelude Therapeutics PRLD Stock Holding History

Jane Street’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$660K Buy
192,963
+81,923
+74% +$215K ﹤0.01% 7393
2025
Q4 		$322K Buy
111,040
+76,218
+219% +$129K ﹤0.01% 8675
2025
Q3 		$50.1K Sell
34,822
-56,931
-62% -$57.1K ﹤0.01% 10353
2025
Q2 		$74.3K Buy
+91,753
New +$79.4K ﹤0.01% 9072
2024
Q4 		– Sell
-10,361
Closed -$21.4K – 10305
2024
Q3 		$21.4K Sell
10,361
-2,587
-20% -$12K ﹤0.01% 9288
2024
Q2 		$49.3K Sell
12,948
-3,440
-21% -$14K ﹤0.01% 8918
2024
Q1 		$77.7K Sell
16,388
-16,589
-50% -$64.5K ﹤0.01% 8621
2023
Q4 		$141K Buy
+32,977
New +$100K ﹤0.01% 8426
2023
Q2 		– Sell
-64,470
Closed -$367K – 9393
2023
Q1 		$367K Buy
64,470
+47,663
+284% +$291K ﹤0.01% 6850
2022
Q4 		$102K Buy
+16,807
New +$108K ﹤0.01% 8083
2022
Q1 		– Sell
-10,241
Closed -$128K – 10875
2021
Q4 		$128K Buy
+10,241
New +$167K ﹤0.01% 9105
2020
Q4 		– Sell
-7,375
Closed -$222K – 7978
2020
Q3 		$222K Buy
+7,375
New +$208K ﹤0.01% 6300

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jane Street's PRLD Position: Q1 2026 in Review

Jane Street increased its Prelude Therapeutics (PRLD) stake by 74% in Q1 2026, buying an estimated $215K and bringing the position to 192,963 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #7393.

Jane Street first reported a position in PRLD in Q3 2020 and has held it in 12 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Jane Street held 192,963 shares of Prelude Therapeutics worth $660K as of Q1 2026.
  • Jane Street bought 81,923 Prelude Therapeutics shares in Q1 2026, an estimated $215K.
  • Prelude Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7393 holding.
  • Jane Street first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 12 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.